Poxel

December 18, 2019

As Nash shifts again, the focus remains on Genfit’s big readout

Genfit investors, who early next year will see the Resolve-It study yield data, digest further developments in the Nash space.

Back to the drawing board for Sumitomo’s deal-making

Yet another project brought in through business development fails, exposing Sumitomo’s limited pipeline.

April 09, 2019

Poxel tastes sweet success at last

The group follows licensing deals with Dainippon and Roivant with a pivotal study win.

May 10, 2017

Interview – Poxel takes high-energy approach to diabetes

May 04, 2017

Novo needs new blood despite earnings relief

September 21, 2016

Allergan’s second move spells showdown with Intercept and Gilead

June 24, 2015

IPO slowdown could signal bubble trouble

April 13, 2015

Floats stumble in Q1 as bubble debate escalates

November 22, 2012

EP Vantage Interview – Poxel treading novel path to diabetes success

July 08, 2010

Serono spin-out Poxel raises €16m to fund phase II diabetes studies